Advances in NAD-Lowering Agents for Cancer Treatment

p21-activated kinases as viable therapeutic targets for the treatment of high-risk Ewing sarcoma

(2021) Shawki L. Qasim et al.   ONCOGENE

Reduced nicotinamide mononucleotide is a new and potent NAD+precursor in mammalian cells and mice

(2021) Rubén Zapata‐Pérez et al.   FASEB JOURNAL

Targeting the NAD+ salvage pathway suppresses APC mutation-driven colorectal cancer growth and Wnt/β-catenin signaling via increasing Axin level

(2020) Chenyang Ye et al.   Cell Communication and Signaling

Bacteria Boost Mammalian Host NAD Metabolism by Engaging the Deamidated Biosynthesis Pathway

(2020) Igor Shats et al.   Cell Metabolism

Anti-angiogenic role of microRNA-23b in melanoma by disturbing NF-κB signaling pathway via targeted inhibition of NAMPT

(2020) Renrong Lv et al.   Future Oncology

OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis

(2020) Lioubov Korotchkina et al.   LEUKEMIA

Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy

(2020) Christine M. Heske   Frontiers in Oncology

Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis

(2020) Giorgia Colombo et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance

(2020) Esther P. Jane et al.   MOLECULAR CANCER RESEARCH

Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy

(2020) Ubaldina Galli et al.   Frontiers in Pharmacology

NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation

(2020) Valentina Audrito et al.   Frontiers in Oncology

Silencing DSCAM-AS1 suppresses the growth and invasion of ER-positive breast cancer cells by downregulating both DCTPP1 and QPRT

(2020) Zhang Yue et al.   Aging-US

Role of NUDIX Hydrolases in NAD and ADP-Ribose Metabolism in Mammals

(2020) V. A. Kulikova et al.   BIOCHEMISTRY-MOSCOW

MicroRNA‑654‑3p enhances cisplatin sensitivity by targeting QPRT and inhibiting the PI3K/AKT signaling pathway in ovarian cancer cells

(2020) Yi‑Chao Niu et al.   Experimental and Therapeutic Medicine

Poly(ADP-ribose) glycohydrolase inhibition sequesters NAD+ to potentiate the metabolic lethality of alkylating chemotherapy in IDH mutant tumor cells

(2020) Hiroaki Nagashima et al.   Cancer Discovery

Local targeting of NAD+ salvage pathway alters the immune tumor microenvironment and enhances checkpoint immunotherapy in glioblastoma

(2020) Ming Li et al.   CANCER RESEARCH

Molecular Profiling of Afatinib-Resistant Non-Small Cell Lung Cancer Cells in vivo Derived from Mice

(2020) Cheng-Ta Chung et al.   PHARMACOLOGICAL RESEARCH

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcoma

(2020) Anna E. Gibson et al.   Oncogenesis

NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion

(2020) Hongwei Lv et al.   Cell Metabolism

NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma

(2020) Valentina Audrito et al.   Cancers

Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer

(2020) Wanheng Zhang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

NAD+ metabolism governs the proinflammatory senescence-associated secretome

(2019) Timothy Nacarelli et al.   NATURE CELL BIOLOGY

Polyunsaturated Fatty Acid Desaturation Is a Mechanism for Glycolytic NAD+ Recycling

(2019) Wondong Kim et al.   Cell Metabolism

Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells

(2019) Cristina Travelli et al.   CANCER RESEARCH

FOXO1 functions in the regulation of nicotinamide phosphoribosyltransferase (Nampt) expression

(2019) Bora Jeong et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Epigenetic regulation of NAMPT by NAMPT-AS drives metastatic progression in triple-negative breast cancer

(2019) Hanwen Zhang et al.   CANCER RESEARCH

Dihydronicotinamide riboside is a potent NAD+ concentration enhancer in vitro and in vivo

(2019) Yue Yang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts

(2019) Mark A. Eckert et al.   NATURE

NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling

(2019) Sudhir Chowdhry et al.   NATURE

Identification of evolutionary and kinetic drivers of NAD-dependent signaling

(2019) Mathias Bockwoldt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

NAMPT and NAPRT, Key Enzymes in NAD Salvage Synthesis Pathway, Are of Negative Prognostic Value in Colorectal Cancer

(2019) Xiao-qin Li et al.   Frontiers in Oncology

Inhibition of NAMPT markedly enhances plasma-activated medium-induced cell death in human breast cancer MDA-MB-231 cells

(2019) Misaki Nagaya et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Suppression of nicotinamide phosphoribosyltransferase expression by miR-154 reduces the viability of breast cancer cells and increases their susceptibility to doxorubicin

(2019) Zahra Bolandghamat Pour et al.   BMC CANCER

PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma

(2019) Nathan R. Fons et al.   Nature Communications

Extracellular nicotinate phosphoribosyltransferase binds Toll like receptor 4 and mediates inflammation

(2019) Antonella Managò et al.   Nature Communications

Targeting c-MYC through Interference with NAMPT and SIRT1 and Their Association to Oncogenic Drivers in Murine Serrated Intestinal Tumorigenesis

(2019) Lydia Brandl et al.   NEOPLASIA

PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors

(2019) Gabriel Mpilla et al.   Cancers

NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer

(2019) Timothy Nacarelli et al.   CANCER RESEARCH

KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells

(2019) Emma Cordover et al.   CHEMICAL RESEARCH IN TOXICOLOGY

High expression of NAMPT in adult T-cell leukemia/lymphoma and anti-tumor activity of a NAMPT inhibitor

(2019) Tomohiro Kozako et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia

(2019) Klaartje Somers et al.   LEUKEMIA

Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide

(2019) Ying Wu et al.   ACS Medicinal Chemistry Letters

Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent

(2019) Anne-Julie Cloux et al.   Oncotarget

A reduced form of nicotinamide riboside defines a new path for NAD+ biosynthesis and acts as an orally bioavailable NAD+ precursor

(2019) Judith Giroud-Gerbetant et al.   Molecular Metabolism

NAD metabolism: Implications in aging and longevity

(2018) Keisuke Yaku et al.   AGEING RESEARCH REVIEWS

Quantitative Analysis of NAD Synthesis-Breakdown Fluxes

(2018) Ling Liu et al.   Cell Metabolism

Down-regulation of NAMPT expression by mir-206 reduces cell survival of breast cancer cells

(2018) Zahra Hesari et al.   GENE

DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade

(2018) Mehdi Touat et al.   JOURNAL OF CLINICAL INVESTIGATION

Inhibition of NAMPT sensitizes MOLT4 leukemia cells for etoposide treatment through the SIRT2-p53 pathway

(2018) Theresa Grohmann et al.   LEUKEMIA RESEARCH

Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody–Drug Conjugates

(2018) Alexei S. Karpov et al.   ACS Medicinal Chemistry Letters

Expression of NAMPT is associated with breast invasive ductal carcinoma development and prognosis

(2018) Shao‑Jie Zhou et al.   Oncology Letters

Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma

(2018) Valentina Audrito et al.   Oncotarget

Targeted delivery of cytotoxic NAMPT inhibitors using antibody-drug conjugates

(2018) Christopher S Neumann et al.   MOLECULAR CANCER THERAPEUTICS

SIRT6 deacetylase activity regulates NAMPT activity and NAD(P)(H) pools in cancer cells

(2018) Giovanna Sociali et al.   FASEB JOURNAL

Long noncoding RNA GACAT3 promotes glioma progression by sponging miR‐135a

(2018) Jing Wang et al.   JOURNAL OF CELLULAR PHYSIOLOGY

The c-MYC/NAMPT/SIRT1 feedback loop is activated in early classical and serrated route colorectal cancer and represents a therapeutic target

(2018) Lydia Brandl et al.   MEDICAL ONCOLOGY

De novo NAD+ synthesis enhances mitochondrial function and improves health

(2018) Elena Katsyuba et al.   NATURE

Tumor cell-secreted PLD increases tumor stemness by senescence-mediated communication with microenvironment

(2018) Sandra Muñoz-Galván et al.   ONCOGENE

Alpha-Amino-Beta-Carboxy-Muconate-Semialdehyde Decarboxylase Controls Dietary Niacin Requirements for NAD+ Synthesis

(2018) Laura Palzer et al.   Cell Reports

The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism

(2017) Molly A. Silvers et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors

(2017) Guoqiang Dong et al.   JOURNAL OF MEDICINAL CHEMISTRY

Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity

(2017) Cristina Travelli et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia

(2017) S Takao et al.   LEUKEMIA

Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration

(2017) Genshi Zhao et al.   MOLECULAR CANCER THERAPEUTICS

Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors

(2017) Julie L. Wilsbacher et al.   MOLECULAR CANCER THERAPEUTICS

From the Cover: Inhibitors of Nicotinamide Phosphoribosyltransferase Cause Retinal Damage in Larval Zebrafish

(2017) Steven Cassar et al.   TOXICOLOGICAL SCIENCES

Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery

(2017) Wei Chen et al.   ACS Medicinal Chemistry Letters

Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer

(2017) Jair Machado Espindola-Netto et al.   Oncotarget

NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis

(2017) Antonio Lucena-Cacace et al.   Oncotarget

A phase 1 trial of GMX1777: An inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT)

(2017) M. J. Pishvaian et al.   JOURNAL OF CLINICAL ONCOLOGY

A novel orally bioavailable compound KPT-9274 inhibits PAK4 and blocks triple negative breast cancer tumor growth

(2017) Chetan Rane et al.   Scientific Reports

NAD + metabolism: Bioenergetics, signaling and manipulation for therapy

(2016) Yue Yang et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer

(2016) Huai-Qiang Ju et al.   CANCER LETTERS

Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines

(2016) D. L. Misner et al.   Cardiovascular Toxicology

Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenstro m Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status

(2016) M. Cea et al.   CLINICAL CANCER RESEARCH

The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development

(2016) T.F. Sumter et al.   CURRENT MOLECULAR MEDICINE

NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177 Lu-DOTATATE Treatment of Neuroendocrine Tumors

(2016) Anna-Karin Elf et al.   JOURNAL OF NUCLEAR MEDICINE

Nicotinamide Riboside Is a Major NAD+ Precursor Vitamin in Cow Milk

(2016) S. A. Trammell et al.   JOURNAL OF NUTRITION

Targeting histone deacetylases in T-cell lymphoma

(2016) Alison J. Moskowitz et al.   LEUKEMIA & LYMPHOMA

Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma

(2016) Amro Aboukameel et al.   MOLECULAR CANCER THERAPEUTICS

Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth

(2016) O. Abu Aboud et al.   MOLECULAR CANCER THERAPEUTICS

A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT

(2016) Marine Barraud et al.   Oncotarget

Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway

(2016) Jun Feng et al.   Biomed Research International

Efficacy and Safety of APO866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma

(2016) Simone M. Goldinger et al.   JAMA Dermatology

Combinative effects of β-Lapachone and APO866 on pancreatic cancer cell death through reactive oxygen species production and PARP-1 activation

(2015) Caroline S. Breton et al.   BIOCHIMIE

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion

(2015) Kensuke Tateishi et al.   CANCER CELL

SIRT1-Mediated eNAMPT Secretion from Adipose Tissue Regulates Hypothalamic NAD+ and Function in Mice

(2015) Myeong Jin Yoon et al.   Cell Metabolism

NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus

(2015) Carles Cantó et al.   Cell Metabolism

APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells

(2015) A. Cagnetta et al.   CLINICAL CANCER RESEARCH

Physiological and pathophysiological roles of NAMPT and NAD metabolism

(2015) Antje Garten et al.   Nature Reviews Endocrinology

Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer

(2015) YANYAN ZHU et al.   ONCOLOGY REPORTS

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer

(2015) Deepak Sampath et al.   PHARMACOLOGY & THERAPEUTICS

Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is a tumoural cytokine released from melanoma

(2015) Ambra A. Grolla et al.   Pigment Cell & Melanoma Research

NAD+ in aging, metabolism, and neurodegeneration

(2015) E. Verdin   SCIENCE

Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid

(2015) Jacqueline M. Tarrant et al.   TOXICOLOGY MECHANISMS AND METHODS

Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expression

(2015) Nadia Sawicka-Gutaj et al.   TUMOR BIOLOGY

NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone

(2015) Z Moore et al.   Cell Death & Disease

Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors

(2015) Sara Duarte-Pereira et al.   Oncotarget

Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid

(2015) Jacqueline M. Tarrant et al.   TOXICOLOGY MECHANISMS AND METHODS

Supplementation of Nicotinic Acid with NAMPT Inhibitors Results in Loss of In Vivo Efficacy in NAPRT1-Deficient Tumor Models

(2015) Thomas O'Brien et al.   NEOPLASIA

Dependence of Tumor Cell Lines and Patient-Derived Tumors on the NAD Salvage Pathway Renders Them Sensitive to NAMPT Inhibition with GNE-618

(2015) Yang Xiao et al.   NEOPLASIA

NAMPT Is the Cellular Target of STF-31-Like Small-Molecule Probes

(2014) Drew J. Adams et al.   ACS Chemical Biology

NAD depletion by FK866 induces autophagy

(2014) Richard A. Billington et al.   Autophagy

Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia

(2014) Valentina Audrito et al.   BLOOD

Synergy between the NAMPT Inhibitor GMX1777(8) and Pemetrexed in Non-Small Cell Lung Cancer Cells Is Mediated by PARP Activation and Enhanced NAD Consumption

(2014) M. Chan et al.   CANCER RESEARCH

On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells

(2014) I. Gehrke et al.   CLINICAL CANCER RESEARCH

Depletion of the Central Metabolite NAD Leads to Oncosis-mediated Cell Death

(2014) Christopher Del Nagro et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Nicotinamide Phosphoribosyltransferase Promotes Epithelial-to-Mesenchymal Transition as a Soluble Factor Independent of Its Enzymatic Activity

(2014) Debora Soncini et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

NQO2 Is a Reactive Oxygen Species Generating Off-Target for Acetaminophen

(2014) Teemu P. Miettinen et al.   MOLECULAR PHARMACEUTICS

Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity

(2014) Daniel Kraus et al.   NATURE

NAD+ depletion by APO866 in combination with radiation in a prostate cancer model, results from an in vitro and in vivo study

(2014) Shuraila F. Zerp et al.   RADIOTHERAPY AND ONCOLOGY

Retinal Toxicity, in vivo and in vitro, Associated with Inhibition of Nicotinamide Phosphoribosyltransferase

(2014) Tanja S. Zabka et al.   TOXICOLOGICAL SCIENCES

The pentose phosphate pathway and cancer

(2014) Krushna C. Patra et al.   TRENDS IN BIOCHEMICAL SCIENCES

Augmentation of NAD+ by NQO1 attenuates cisplatin-mediated hearing impairment

(2014) H-J Kim et al.   Cell Death & Disease

Regulation of the pentose phosphate pathway in cancer

(2014) Peng Jiang et al.   Protein & Cell

Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)

(2013) Xiaozhang Zheng et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity

(2013) A. Cagnetta et al.   BLOOD

The Endogenous Tryptophan Metabolite and NAD+ Precursor Quinolinic Acid Confers Resistance of Gliomas to Oxidative Stress

(2013) F. Sahm et al.   CANCER RESEARCH

Next-Generation NAMPT Inhibitors Identified by Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens

(2013) Christina J. Matheny et al.   CHEMISTRY & BIOLOGY

Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors

(2013) D. S. Shames et al.   CLINICAL CANCER RESEARCH

SIRT3 regulates cell proliferation and apoptosis related to energy metabolism in non-small cell lung cancer cells through deacetylation of NMNAT2

(2013) HONGQI LI et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Structure-Based Discovery of Novel Amide-Containing Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors

(2013) Xiaozhang Zheng et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pharmacological activation of NQO1 increases NAD+ levels and attenuates cisplatin-mediated acute kidney injury in mice

(2013) Gi-Su Oh et al.   KIDNEY INTERNATIONAL

The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody

(2013) Aimable Nahimana et al.   LEUKEMIA & LYMPHOMA

NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink

(2013) Olesya A Ulanovskaya et al.   Nature Chemical Biology

Nicotinamide Phosphoribosyl Transferase (Nampt) Is a Target of MicroRNA-26b in Colorectal Cancer Cells

(2013) Chenpeng Zhang et al.   PLoS One

Intracellular NAD+depletion induces autophagic death in multiple myeloma cells

(2012) Michele Cea et al.   Autophagy

Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition

(2012) M. Cea et al.   BLOOD

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells

(2012) Ilirjana Bajrami et al.   EMBO Molecular Medicine

Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT) Activity by Small Molecule GMX1778 Regulates Reactive Oxygen Species (ROS)-mediated Cytotoxicity in a p53- and Nicotinic Acid Phosphoribosyltransferase1 (NAPRT1)-dependent Manner

(2012) David Cerna et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Nicotinamide phosphoribosyltransferase (NAMPT) is over-expressed in melanoma lesions

(2012) Elena Maldi et al.   Pigment Cell & Melanoma Research

Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas

(2011) UFFE HØGH OLESEN et al.   APMIS

Characterization of human nicotinate phosphoribosyltransferase: Kinetic studies, structure prediction and functional analysis by site-directed mutagenesis

(2011) Lucia Galassi et al.   BIOCHIMIE

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Modulating Endogenous NQO1 Levels Identifies Key Regulatory Mechanisms of Action of  -Lapachone for Pancreatic Cancer Therapy

(2011) L. S. Li et al.   CLINICAL CANCER RESEARCH

A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity

(2011) Huei-Jiun Yang et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Reciprocal Potentiation of the Antitumoral Activities of FK866, an Inhibitor of Nicotinamide Phosphoribosyltransferase, and Etoposide or Cisplatin in Neuroblastoma Cells

(2011) C. Travelli et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil

(2011) Xiang-Ming Che   ONCOLOGY REPORTS

Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells

(2011) Michele Cea et al.   PLoS One

The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop

(2011) A. Menssen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality

(2011) D. A. Chan et al.   Science Translational Medicine

The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression

(2010) Jean-Philippe Coppé et al.   Annual Review of Pathology-Mechanisms of Disease

Efficacy of Combining GMX1777 with Radiation Therapy for Human Head and Neck Carcinoma

(2010) H. Kato et al.   CLINICAL CANCER RESEARCH

The Secret Life of NAD+: An Old Metabolite Controlling New Metabolic Signaling Pathways

(2010) Riekelt H. Houtkooper et al.   ENDOCRINE REVIEWS

Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells

(2010) Gabriele Zoppoli et al.   EXPERIMENTAL HEMATOLOGY

A Preclinical Study on the Rescue of Normal Tissue by Nicotinic Acid in High-Dose Treatment with APO866, a Specific Nicotinamide Phosphoribosyltransferase Inhibitor

(2010) U. H. Olesen et al.   MOLECULAR CANCER THERAPEUTICS

NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response

(2010) B Wang et al.   ONCOGENE

Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression

(2010) A. Le et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777

(2009) Pierre Beauparlant et al.   ANTI-CANCER DRUGS

Virtual screening to identify lead inhibitors for bacterial NAD synthetase (NADs)

(2009) Whitney Beysselance Moro et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies

(2009) A. Nahimana et al.   BLOOD

Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data

(2009) Anne von Heideman et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The NMN/NaMN adenylyltransferase (NMNAT) protein family

(2009) Corinna Lau   Frontiers in Bioscience-Landmark

The Small Molecule GMX1778 Is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors

(2009) M. Watson et al.   MOLECULAR AND CELLULAR BIOLOGY

Crystal structure of Rattus norvegicus Visfatin/PBEF/Nampt in complex with an FK866-based inhibitor

(2009) Gil Bu Kang et al.   MOLECULES AND CELLS

Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE

(2009) Santina Bruzzone et al.   PLoS One

Nicotinic Acid, Nicotinamide, and Nicotinamide Riboside: A Molecular Evaluation of NAD+ Precursor Vitamins in Human Nutrition

(2008) Katrina L Bogan et al.   Annual Review of Nutrition

Anticancer agent CHS-828 inhibits cellular synthesis of NAD

(2008) Uffe Høgh Olesen et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS